New SEISMIQ 4CE device shows high success and safety in treating severe coronary artery disease.

Boston Scientific's SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter demonstrated strong safety and effectiveness in the FRACTURE trial for severe coronary artery disease. The trial showed a 93.3% rate of freedom from major cardiac events and 93.7% procedural success, with 100% stent delivery success. This device uses acoustic waves to break calcium in arteries, aiding stent placement and improving outcomes. The results support regulatory submissions and could expand treatment options for complex coronary artery disease cases.